पिटोलिसेंट के इंटरैक्शन

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (आइवाब्राडिन लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (ऑक्सालिप्लैटिन लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (प्रोपाफेनोन लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Drugs that Prolong the QT Interval : Avoid concomitant use. (फेनोबार्बिटोन लेबल, दवाओं के इंटरैक्शन)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (फॉस्कारनेट लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (फॉस्फोमाइसिन लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (मिर्टाज़ापिन लेबल, दवाओं के इंटरैक्शन)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (लोपिनाविर और रिटोनाविर लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (वेपडेजेस्ट्रेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Avoid the concomitant use of drugs known to prolong the QTc interval. (सर्ट्रालिन लेबल, दवाओं के इंटरैक्शन)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Prevention or Management: Avoid centrally acting H1 receptor antagonists. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (आइसोफ्लुरेन लेबल, चेतावनियां और सावधानियां)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (आरफॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (एरिबुलिन लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (गोसेरेलिन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ट्रिप्टोरेलिन लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (डेसफ्लुरेन लेबल, चेतावनियां और सावधानियां)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (पैसिरियोटाइड लेबल, दवाओं के इंटरैक्शन)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (पोनेसिमोड लेबल, दवाओं के इंटरैक्शन)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (प्राइमाक्वीन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

…prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte… (फेंटानिल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (बिस्मथ सबसाइट्रेट, मेट्रोनिडाज़ोल और टेट्रासाइक्लिन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (ब्यूप्रेनॉर्फिन लेबल, चेतावनियां और सावधानियां)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (मेट्रोनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

…like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (रिल्पिविरिन लेबल, चेतावनियां और सावधानियां)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (रोक्यूरोनियम लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ल्यूप्रोलाइड लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (सुनिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (सेवोफ्लुरेन लेबल, चेतावनियां)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (हाइड्रोकोडोन लेबल, चेतावनियां और सावधानियां)